All fields are required.

Close Appointment form

Management Team

Improving patient outcomes with innovative drug therapies.

Robert L. Chioini

Founder and Chief Executive Officer

Robert L. Chioini, 53, is the Founder and Chief Executive Officer of Rockwell Medical, Inc. Mr. Chioini served as the Chairman from March 2000 through March 2018, as well as the Chief Executive Officer since January 1995. In addition, Mr. Chioini is a Board Member of Medical Mainstreet, an alliance of world-class hospitals, universities, medical device and biopharmaceutical companies creating a global center of innovation in health care, research and development, education and commercialization in the life sciences industry in Oakland County, Michigan. Prior to founding Rockwell, Mr. Chioini served as Regional Sales Manager for Dial Medical of Florida, Inc., from 1993 to 1995, which was then acquired by Gambro HealthCare, Inc. Earlier in his career, Mr. Chioini served in sales, management and marketing capacities with medical manufacturing companies. Mr. Chioini is a graduate of Michigan State University and earned his Bachelor’s degree in 1987.

Thomas E. Klema

Vice President, Chief Financial Officer, Treasurer and Secretary

Thomas E. Klema, CPA/MBA, 63, is the Vice President of Finance, Chief Financial Officer, Treasurer and Secretary of Rockwell Medical and has served in that position since January 1999. Prior to joining Rockwell, Mr. Klema served as the Vice President of Finance and Administration for Whistler Corporation. Previously, Mr. Klema held senior management roles at Molson’s Diversey subsidiary, which was acquired by Unilever. While at the Molson Companies and Unilever, Mr. Klema served as Vice President of Finance, Administration and Business Development. Mr. Klema earned his Bachelor’s Degree in 1976 and his Master of Business Administration in Finance Degree in 1977 from Michigan State University.

Ajay Gupta, M.D.

Chief Scientific Officer

Ajay Gupta, 59 is the Chief Scientific Officer and has served in that position since he joined the company in June of 2009. Dr. Gupta has been a member of Rockwell’s Scientific Advisory Board since November, 2005. From 2002 to 2009, Dr. Gupta was an Associate Professor of Medicine at UCLA and Charles Drew University Schools of Medicine in Los Angeles where he had an active nephrology practice. Dr. Gupta is the inventor of dialysate iron therapy using Soluble Ferric Pyrophosphate (SFP) as well as the inventor of intravenous (IV) iron therapy using slow continuous infusion of SFP. He has filed a number of patents in the areas of drugs, medical devices and diagnostic tests. Dr. Gupta earned his MBBS degree and completed his residency in Internal Medicine from All India Institute of Medical Sciences (AIIMS), New Delhi. In 1990, he completed a Nephrology Clinical/Research Fellowship from Washington University, St. Louis, Missouri. He has served on the faculty at Washington University, St. Louis; State University of New York, Syracuse; University of Alabama, Birmingham and Henry Ford Hospital, Detroit; MI. Dr. Gupta is the founder and Chairman of the Indian Society for Bone and Mineral Research; earned his MBBS degree and completed his residency in Internal Medicine for AII India Institute of Medical Sciences, New Delhi; has completed a clinical fellowship in Nephrology from Wayne State University, Detroit, Michigan and a research fellowship in Nephrology from Washington University, St. Louis, Missouri.

Raymond D. Pratt, M.D.

Chief medical Officer

Raymond D. Pratt, M.D, 66, is the Chief Medical Officer since he joined the company in April, 2012. Dr. Pratt was Vice President R&D and as the scientific leader in its Emerging Business and Renal Business Units at Shire PLLC. Previous roles at Shire included Vice President Global Clinical Medicine and Global Clinical Affairs and head of US Clinical Development. Dr. Pratt was instrumental in the FDA approval of Fosrenol ESRD indication and CKD non-dialysis indication in the European Union and United States. He was responsible for three new drug applications as well as multiple EU applications. He has managed ten different drugs through all stages of global development for renal and other indications and has extensive experience appearing before the FDA. Prior to Shire, Dr. Pratt was Senior Director, Clinical Research and Development at Eisai Medical Research from 1994 to 2003, where he was head of Central Nervous System and Internal Medicine clinical development. Dr. Pratt received his M.D. from the University of Illinois College of Medicine and completed his nephrology fellowship at the Walter Reed Army Medical Center and served as the Asst. Chief of Nephrology Services and Director of Dialysis Services. He has served as an Assistant Professor Johns Hopkins University Department of Medicine and Nephrology from 1989 to 1993.